Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
04 apr 2016 - 08:05
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Probiodrug announces results of chronic toxicology studies with PQ912, its 'first in class' Glutaminyl Cyclase (QC) inhibitor for the treatment of Alzheimer's disease
Bericht
Probiodrug announces results of chronic toxicology studies with PQ912, its 'first in class' Glutaminyl Cyclase (QC) inhibitor for the treatment of Alzheimer's disease
Favourable results enable longer patient treatment
HALLE/SAALE, Germany, 04 April 2016 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), today announced that it has concluded the assessment of its chronic toxicology studies with its lead candidate PQ912, currently under development for AD in a clinical phase 2 study (SAPHIR).
Gerelateerde downloads
Datum laatste update: 27 december 2025